多替拉韦/利匹韦林维持双药治疗中治疗药物监测与48周病毒学应答
该回顾性多中心研究纳入209例病毒学抑制的HIV-1感染者,转换为多替拉韦/利匹韦林双药维持治疗后,用贝叶斯法估计谷浓度并分析其与病毒载量的关系。
要点
- 双药维持治疗中,病毒学复制者更常见亚治疗谷浓度。
- 多替拉韦谷浓度阈值640 ng/mL,利匹韦林阈值50 ng/mL。
- 48周病毒载量>50拷贝/mL者占7.1%,停药者占9.1%。
核心结论
- 多数接受多替拉韦/利匹韦林维持双药治疗者48周病毒载量<50拷贝/mL,但亚治疗谷浓度者病毒复制更频繁。
研究设计与样本
- 回顾性分析9个法国中心HIV感染者双药治疗的治疗药物监测数据,纳入209例,用贝叶斯法估计谷浓度。
主要发现
- 48周时19例(9.1%)停药,15例(7.1%)病毒载量>50拷贝/mL。
关键数值与推荐
- 亚治疗阈值定义为多替拉韦谷浓度<640 ng/mL、利匹韦林谷浓度<50 ng/mL。
临床怎么用
- 对多替拉韦/利匹韦林双药维持治疗者,可考虑治疗药物监测识别亚治疗谷浓度以评估病毒复制风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended as a switch option in virologically suppressed HIV patients. Literature suggests that virological failure with dual therapy could possibly relate to subtherapeutic drug concentrations. In this study, we aimed at describing the DTG and RPV trough plasma concentrations (Cmin) and plasma HIV-1 RNA viral load (VL) during maintenance dual therapy. METHODS: We performed a retrospective analysis of DTG and RPV therapeutic drug monitoring in people living with HIV/AIDS (PLWHA) with dual therapy in 9 French centres. DTG and RPV trough plasma concentrations were estimated using a Bayesian approach to predict Cmin. The relationship between the pharmacokinetics of DTG and RPV and VL > 50 copies (cp)/mL was explored using joint nonlinear mixed models. The frequency of subtherapeutic threshold (DTG Cmin below 640 ng/mL and RPV Cmin below 50 ng/mL) were compared between PLWHA presenting VL > 50 cp/mL or not during the study. RESULTS: At baseline, 209 PLWHA were enrolled in the study. At week 48, 19 people living with HIV/AIDS (9.1%) discontinued their treatment and 15 PLWHA (7.1%) exhibited VL > 50 cp/mL. Six PLWHA out of 15 (40.0%) with VL > 50 cp/mL during the follow-up had at least 1 Cmin below the respective thresholds while only 26/194 patients (13.4%) without virological replication had at least 1 concentration below the threshold (P = .015). CONCLUSION: A majority of PLWHA receiving DTG/RPV maintenance dual therapy demonstrated VL < 50 cp/mL but virological replication was more frequent in people living with HIV/AIDS with subtherapeutic Cmin.
引用
- Lemaitre F, Lagoutte-Renosi J, Gagnieu MC, et al. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study). Br J Clin Pharmacol. 2023. PMID: 37602480. doi:10.1111/bcp.15890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。